Press Releases Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
1.65 ^USD	-6.78%		-25.34%	-48.11%

Jun. 04	Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	CI
May. 15	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	Jun. 04	GL
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024	Jun. 04	AQ
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024	May. 20	GL
Lumos: Q1 Earnings Snapshot	May. 14	AQ
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results	May. 14	GL
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024	May. 09	GL
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings	Apr. 18	GL
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042	Mar. 20	GL
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update	Mar. 07	GL
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	Feb. 26	GL
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	Feb. 26	AQ
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 05	GL
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 05	AQ
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	Jan. 04	GL
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	Jan. 04	AQ
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	Nov. 21	GL
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency	Nov. 21	AQ
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November	Nov. 20	GL
Lumos: Q3 Earnings Snapshot	Nov. 07	AQ
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates	Nov. 07	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Press Releases

Filters